Immuneering Corporation (IMRX) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the engineering conference call to discuss the company's third quarter 2025 financial results and share investigator-presented clinical case studies in pancreatic patients. At this time, all participants are in listen-only mode. Following management's prepared remarks, we will hold a Q&A session. To ensure that we have ample time to address everyone's question, we would like to ask each person to limit themselves to one question and one follow-up. As a reminder, this call is being recorded today, Wednesday, November 12th, 2025. I would now like to turn the call conference over to Lawrence Watts of New Street Investor Relations. Thank you, operator. Joining us on the call today from engineering are Chief Executive Officer Ben Zeskin, Chief Scientific Officer Brett Hall, Chief Medical Officer Igor Moshchansky, Chief Accounting Officer and Treasurer, Mellie Morales, and E.B. Breakwood, our Chief Business Officer. During this call, management and our three investigators will refer to slides that you can find in the updated version of our corporate deck available in PDF on our I.R. website. Throughout this call, management will be making forward-looking statements, including statements related to its Phase 2A trial of the Teddy Messimp, as well as the timing of additional data from the study and the company's development plans. Our actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of risks and uncertainties. Factors that could cause these results to be different from these statements include factors the company describes in its security filings, including its annual report on Form 10-K and our quarterly reports on Form 10-Q. Engineering undertakes no duty or obligation to update...